An international study looking at the treatment of cancer of the penis that has spread to inguinal or pelvic lymph nodes

This trial is open to men aged 18 and over who have been diagnosed with squamous cell carcinoma of the penis (the most common type of penile cancer). To be eligible, the cancer must have spread to the lymph nodes in the groin or pelvis, but it must not have spread to distant parts of the body such as the lungs, liver, or bones.

Men taking part need to be well enough to manage day-to-day activities and handle treatment, which doctors check using a fitness score. Good kidney and liver function are also required, as confirmed by standard blood tests, to ensure the body can safely process chemotherapy drugs.

Men cannot join this study if they have rare non-squamous forms of penile cancer, cancer that started in the urethra, or cancer that has already spread widely across the body. You also cannot join if you have already had chemotherapy or radiotherapy for this cancer, or if you have had another active cancer requiring treatment in the last three years (apart from common, non-melanoma skin cancers). Men who are sexually active must agree to use reliable contraception during the study.

Taking part begins with a detailed check-up, including scans (such as CT, MRI, or PET scans), physical checks of your groin, and routine blood tests to see if the trial is right for you. If you join, a computer program will assign your treatment plan. Depending on your group, you may receive chemotherapy through a drip in hospital over several weeks, undergo surgery to remove the affected lymph nodes and tumour, or receive radiotherapy aimed at your pelvis. The active treatment phase typically lasts several months. After your treatment is complete, you will have regular clinic visits, blood tests, and scans over a number of years so the medical team can closely track your recovery, health, and wellbeing.